Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) rose 6.2% on Monday . The company traded as high as $2.74 and last traded at $2.74, with a volume of 1,323,898 shares. The stock had previously closed at $2.58.

ARWR has been the subject of a number of research reports. ValuEngine upgraded shares of Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, August 24th. Piper Jaffray Companies restated a “hold” rating and set a $2.00 target price on shares of Arrowhead Pharmaceuticals in a report on Friday, July 28th. Finally, Jefferies Group LLC restated a “hold” rating and set a $2.00 target price on shares of Arrowhead Pharmaceuticals in a report on Friday, August 4th. One analyst has rated the stock with a sell rating and five have issued a hold rating to the company’s stock. Arrowhead Pharmaceuticals has an average rating of “Hold” and a consensus target price of $1.80.

The firm has a 50 day moving average price of $1.82 and a 200 day moving average price of $1.79. The firm’s market capitalization is $197.40 million.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.06. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%. The firm had revenue of $9.34 million during the quarter, compared to analyst estimates of $5.29 million. On average, equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post ($0.42) EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. LMR Partners LLP purchased a new position in Arrowhead Pharmaceuticals during the second quarter valued at about $467,000. Wells Fargo & Company MN raised its position in Arrowhead Pharmaceuticals by 144.8% in the first quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock valued at $278,000 after buying an additional 88,933 shares during the last quarter. SG Americas Securities LLC raised its position in Arrowhead Pharmaceuticals by 287.9% in the first quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 74,776 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in Arrowhead Pharmaceuticals by 414.7% in the first quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 53,500 shares during the last quarter. Finally, Virtu KCG Holdings LLC raised its stake in Arrowhead Pharmaceuticals by 115.6% in the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 53,215 shares in the last quarter. Hedge funds and other institutional investors own 20.63% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price Up 6.2%” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/30/arrowhead-pharmaceuticals-inc-arwr-stock-price-up-6-2.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.